Evidence map›Paper›PMID 36532548›Full record

ArticleFrontiers in nutrition2022

Dietary supplementation with Mexican foods,

Rebeca Rosas-Campos, Alejandra Meza-Rios, J Samael Rodriguez-Sanabria, Ricardo De la Rosa-Bibiano, Karina Corona-Cervantes, Jaime García-Mena, Arturo Santos, Ana Sandoval-Rodriguez, Juan Armendariz-Borunda

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Frontiers in nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07592013 (Effect of Ancestry Supplementation on the Abundance of Beneficial Bacterial Genera in the Gut Microbiota in Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07592013 naenrolling by invitationnot on this mapstarted 2025, after this paper: background citation

Effect of Ancestry Supplementation on the Abundance of Beneficial Bacterial Genera in the Gut Microbiota in Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

TypeinterventionalSponsorUniversity of GuadalajaraRan2025 to 2027Enrolled60ConditionsMASLDArmsAncestry, Placebo
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Gut microbiota mediates semaglutide attenuation of diabetes-associated cognitive decline.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  4. Modulation of the gut microbiota by dietary intervention withBioscience of microbiota, food and health · 2025
    Article
  5. Article
  6. Usefulness ofNutrients · 2024
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Rebeca Rosas-CamposDepartment of Molecular Biology and Genomics, Health Sciences University Center, Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, Guadalajara, Mexico.
Alejandra Meza-RiosDepartment of Molecular Biology and Genomics, Health Sciences University Center, Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, Guadalajara, Mexico.
J Samael Rodriguez-SanabriaDepartment of Molecular Biology and Genomics, Health Sciences University Center, Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, Guadalajara, Mexico.
Ricardo De la Rosa-BibianoDepartment of Molecular Biology and Genomics, Health Sciences University Center, Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, Guadalajara, Mexico.
Karina Corona-CervantesDepartamento de Genética y Biología Molecular, Cinvestav, Ciudad de México, Mexico.
Jaime García-MenaDepartamento de Genética y Biología Molecular, Cinvestav, Ciudad de México, Mexico.
Arturo SantosTecnológico de Monterrey, EMCS, Guadalajara, Mexico.
Ana Sandoval-RodriguezDepartment of Molecular Biology and Genomics, Health Sciences University Center, Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, Guadalajara, Mexico.
Juan Armendariz-BorundaDepartment of Molecular Biology and Genomics, Health Sciences University Center, Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, Guadalajara, Mexico.
Universidad de Guadalajara · MXCenter for Research and Advanced Studies of the National Polytechnic Institute · MXTecnológico de Monterrey · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: An obesogenic diet, a diet high in saturated fats and sugars, is a risk factor for the development of multiple obesity-related diseases. In this study, our aim was to evaluate the effect of supplementation with a mixture of Mexican functional foods (MexMix), Methods: For this study, 18 male C57BL/6J mice were used, which were divided into three groups: (1) control group: normal diet (ND), (2) HF/FS group: high-fat diet along with 4.2% fructose/sucrose and water ( Results: MexMix mice showed significantly reduced body weight, liver weight, visceral fat, and epididymal fat compared with HF/FS mice. Levels of triglycerides, cholesterol, LDL cholesterol, insulin, glucose, GIP, leptin, PAI-1, and resistin were also significantly reduced. For identifying the gut microbiota in the model, 16S rRNA gene sequencing analysis was performed, and the results showed that MexMix supplementation increased the abundance of Conclusion: Hence, supplementation with MexMix food might represent a potential strategy for the treatment of obesity and other diseases associated with excessive intake of fats and sugars.

Indexed as

Acheta domesticusMexican dietobesityobesogenic dietOpuntia ficus indicaTheobroma cacao

Identifiers

PMID36532548
PMCPMC9755723
OpenAlexW4311192186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.